FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Ulcerative Colitis

Asacol (mesalamine) (by Procter & Gamble), Approved August 1997
Treatment of ulcerative colitis

Colazal (balsalazide disodium) (by Salix Pharmaceuticals), Approved July 2000
Mild to moderately active ulcerative colitis

Entyvio (vedolizumab) (by Millenium Pharmaceuticals), Approved May of 2014
For the treatment of adults with ulcerative colitis and Crohn's disease

Simponi (golimumab) (by Centocor Ortho Biotech), Approved April 2009
For the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Simponi (golimumab) (by Janssen Biotech), Aproved May 2013
For the treatment of ulcerative colitis

Uceris (budesonide) (by Santarus), Approved January 2013
For the treatment of ulcerative colitis

Ulcers

Carrington patch (by Carrington Laboratories), Approved May 1996
Treatment for canker sores

Ocuflox (ofloxacin opthalmic solution) 0.3% (by Allergan), Approved May 1996
Treatment for corneal ulcers

Otezla (apremilast) (by Celgene), Approved July 2019
For the treatment of adults with oral ulcers associated with Behçet’s Disease

Ranitidine Tablets (by Apotex), Approved September 1997
Generic equivalent of Zantac

Vimovo (naproxen + esomeprazole) (by AstraZeneca), Approved April 2010
For the treatment of arthritis in patients at risk for NSAID-associated ulcers

Urinary Incontinence

Anturol (oxybutynin) Gel (by Antares Pharma), Approved December 2011
For the treatment of overactive bladder

Interstim Continence Control Therapy (by Medtronic), Approved September 1997
Treatment for incontinence

Myrbetriq (mirabegron) (by Astellas Pharma US, Inc), Approved June 2012
For the treatment of overactive bladder

Urinary Tract Infections

Avycaz (ceftazidime-avibactam) (by Actavis), Approved February 2015
For the treatment of complicated intra-abdominal and urinary tract infections

Doribax (doripenem) (by Johnson & Johnson), Approved October 2007
For the treatment of intra-abdominal infections and urinary tract infections

Monurol (by Forest Laboratories), Approved December 1996
Treatment for uncomplicated urinary tract infection

Recarbrio (imipenem, cilastatin, and relebactam) (by Merck), Approved July 2019
For the treatment of complicated intra-abdominal and urinary tract infections

Vabomere (meropenem and vaborbactam) (by The Medicines Company), Approved August 2017
For the treatment of complicated urinary tract infections

Zemdri (plazomicin) (by Achaogen), Approved June 2018
For the treatment of complicated urinary tract infections

Zerbaxa (ceftolozane + tazobactam) (by Merck), Approved December 2014
For the treatment of complicated intra-abdominal and urinary tract infections and bacterial pneumonia

Urologic Cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved February 2017
For the treatment of metastatic urothelial carcinoma

Urothelial Tract Cancer

Balversa (erdafitinib) (by Janssen Oncology), Approved April 2019
For the treatment of locally advanced or metastatic urothelial carcinoma

Imfinzi (durvalumab) (by AstraZeneca), Initially approved May 2017
For the treatment of advanced or metastatic urothelial carcinoma and Stage III non-small cell lung cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved February 2017
For the treatment of metastatic urothelial carcinoma

Urticaria

Gastrocrom Oral Concentrate (cromolyn sodium) (by Rhone Poulenc Rorer), Approved April 1996
Treatment for mastocytosis

Uveitis

Humira (adalimumab) (by Abbvie), Approved July 2016
For the treatment of uveitis